Hangzhou Tigermed Consulting Co., Ltd.

Hangzhou Tigermed Consulting Co., Ltd. operates as a contract research organization (CRO) in China and internationally. The supplied evidence describes its work as professional services for the full process of clinical trials supporting new-drug development. The available evidence does not specify the company’s founding date, headquarters, founder, ownership, listing status, named executives, or individual products. Its service area is identified at the level of clinical-trial support for new-drug development; more detailed service offerings and market-specific operations are not established here.

The supplied evidence identifies Hangzhou Tigermed Consulting Co., Ltd. as a contract research organization operating in China and internationally. It describes the company’s work as professional services covering the clinical-trial process for new-drug development. No dated history, founding information, leadership changes, acquisitions, or other historical turning points are included in the available evidence, so a more detailed chronology cannot be established.

A contract research organization providing professional clinical-trial services for new-drug development.

• Clinical-trial services for new-drug development

  Professional services for the clinical-trial process supporting new-drug development.

• 2026

  Actual Controllers Penalized for Disclosing Equity Changes Nearly 7 Years Late

  Actual controllers Ye Xiaoping and Cao Xiaochun failed to timely disclose cumulative shareholding changes reaching 5% in 2019 and a 1% reduction in 2022, and only supplemented disclosure in 2026; in 2015, a subsidiary was also cited as non-compliant in a clinical data self-inspection. The two are planned to be fined RMB 500,000 each.

  Source

Read more

• 2021.07.15

  Reported2021.07.15

  Adlai Nortye completes $100 million Series D financing[4]Adlai Nortye完成1亿美元D轮融资finanznachrichten.de

  Adlai Nortye announced that it completed a $100 million Series D financing round co-led by SDIC Fund Management and Tigermed, with proceeds intended to support drug development and portfolio expansion.

• Unconfirmed

  Reported2020.10.06

  Heji Pharmaceutical completes Series A funding[5]和剂药业完成A轮融资finance.sina.com.cn

  Heji Pharmaceutical announced that it completed a 280 million yuan Series A financing, with Baitai Pharma, Hisun Pharmaceutical, Tigermed, and Pucheng Investment among the investors.

• 2020.07.28

  Reported2020.07.28

  Tigermed begins Hong Kong IPO offering[6]泰格医药启动香港IPO招股finance.sina.com.cn

  Hangzhou Tigermed announced that its Hong Kong IPO subscription began on July 28, 2020, with a planned listing on August 7.

• 2020.06.28

  Reported2020.06.28

  Yahong Medicine completes Series C+ funding[7]亚虹医药完成C+轮融资prnasia.com

  Yahong Medicine announced that it had completed its Series C+ funding round. The funds will support existing pipeline products and preparations for commercialization of new products.

• Unconfirmed

  WEN CHEN resigns as Tigermed deputy general manager[8]WEN CHEN辞去泰格医药副总经理职务sc.stock.cnfol.com

  Hangzhou Tigermed Consulting Co., Ltd. announced that deputy general manager WEN CHEN resigned for personal reasons and would hold no further position at the company.

• Unconfirmed

  Reported2020.02.19

  Canbridge Pharmaceuticals completes US$98 million Series D financing[9]北海康成完成9800万美元D轮融资finance.sina.com.cn

  Canbridge Pharmaceuticals announced that it had completed a US$98 million Series D financing. General Atlantic and WuXi AppTec led the round, and each had the right to make an additional investment of up to US$10 million subject to agreed conditions.

Read more

1. 1Hangzhou Tigermed Consulting Co.,Ltd - Wikidatawikidata.org
2. 2Actual Controllers Penalized for Disclosing Equity Changes Nearly 7 Years Latebjnews.com.cn
3. 3Actual Controllers Penalized for Disclosing Equity Changes Nearly 7 Years Latenbd.com.cn
4. 4Adlai Nortye完成1亿美元D轮融资finanznachrichten.de
5. 5和剂药业完成A轮融资finance.sina.com.cn
6. 6泰格医药启动香港IPO招股finance.sina.com.cn
7. 7亚虹医药完成C+轮融资prnasia.com
8. 8WEN CHEN辞去泰格医药副总经理职务sc.stock.cnfol.com
9. 9北海康成完成9800万美元D轮融资finance.sina.com.cn
10. 10北海康成完成9800万美元D轮融资，泛大西洋投资集团和药明康德领投tech.sina.com.cn
11. 11和剂药业完成2.8亿元A轮融资，与美国Corvus Pharmaceuticals达成战略合作finance.sina.com.cn
12. 12泰格医药：关于公司高管辞职的公告finance.sina.com.cn